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Background. Recurrent ischemic stroke is associated with adverse neurological outcome in patients with atrial fibrillation.
There is very scarce information regarding the neurological outcome of atrial fibrillation patients undergoing repeated systemic
thrombolysis after early recurrent ischemic stroke. Clinical Case and Discussion. We describe a case of a 76-year-old woman with
known paroxysmal atrial fibrillation who was admitted because of an acute right middle cerebral artery ischemic stroke and who
underwent repeated systemic thrombolysis within 110 hours. The patient underwent systemic thrombolysis after the first ischemic
stroke with almost complete neurological recovery. On the fourth day after treatment, an acute left middle cerebral artery ischemic
stroke was diagnosed and she was treated with full-dose intravenous recombinant tissue plasminogen activator. A hemorrhagic
transformation of the leftmiddle cerebral artery infarctionwas noted on follow-up cranial computed tomographic scans.Thepatient
did not recover from the second cerebrovascular event and died 25 days after admission. Conclusion. To the best of our knowledge,
this is the second case reporting the adverse neurological outcome of a patient with diagnosis of atrial fibrillation undergoing
repeated systemic thrombolysis after early recurrent ischemic stroke. Our report represents a contribution to the scarce available
evidence suggesting that repeated systemic thrombolysis for recurrent ischemic stroke should be avoided.
1. Introduction
There is strong evidence that treatment of acute ischemic
strokewith intravenous (IV) recombinant tissue plasminogen
activator (rtPA) reduces long-term disability [1]. However,
because of the risk of major bleeding, there is a need for
careful selection of potentially treatable patients. Eligibility
standards are based on inclusion and exclusion criteria used
in large randomized clinical trials [2–4]. Among several
contraindications, IV rtPA should not be used in patientswho
had suffered an ischemic stroke within the previous 3months
[1]. The repeated use of IV rtPA in the 3-month window
may be associated to a higher risk of cerebral bleeding
and to potential anaphylactic reactions [5]. There is scarce
information about the repeated use of IV rtPA for early
recurrent ischemic stroke [6–9], and serious concerns have
been raised regarding this matter [10].
We report a case of repeated used of IV rtPA within
110 hours in a patient with early recurrent ischemic stroke
associated to atrial fibrillation, and we discuss its pathophys-
iological, clinical, and prognostic implications.
2. Clinical Case and Discussion
A 76-year-old woman was admitted to the Instituto de
Investigaciones Me´dicas “Alfredo Lanari” because of left-
sided numbness and slurred speech. On neurologic exami-
nation, she was not alert but arousable by minor stimulation.
Examination of visual fields revealed a left homonymous
hemianopia. A total paralysis of the left lower face was
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Figure 1: Cranial CT scan performed 100 minutes after first ischemic stroke onset (Panel a) and 24 hours after first IV thrombolysis (Panel b)
shows a right lenticular hypodensity compatible with an acute cerebral infarction (black arrows). Cranial CT scan performed 30minutes after
second ischemic stroke onset (Panel c) and 48 hours after second systemic thrombolysis (Panel d) shows a subacute right lenticular infarction
(black arrows) and a new predominantly subcortical ischemic lesion in the anterior region of the left middle cerebral artery territory with a
PH2 hemorrhage (white arrows).
noted, and no movement could be elicited on the left arm
and left leg. A left hemisensory deficit, moderate dysarthria,
and profound left hemi-inattention were also evidenced.
National Institutes of Health Stroke Scale (NIHSS) score was
18 points. Laboratory results were unremarkable. Head com-
puted tomography (CT) scan performed 100 minutes after
symptoms onset showed a subtle hypodensity of the right
lenticular nucleus (Figure 1(a)). Electrocardiogram showed
sinus rhythm.
The patient had a history hypertension, paroxysmal
atrial fibrillation, hyperlipidemia, dilated cardiomyopathy,
two acute myocardial infarctions, congestive heart failure,
and pulmonary hypertension. She had undergone coro-
nary artery stenting after the second myocardial infarction,
and an implantable cardioverter-defibrillator was placed 6
years after. She was taking acetylsalicylic acid (100mg/day),
spironolactone (25mg/day), furosemide (20mg/day), carv-
edilol (6,125mg BID), and simvastatin (20mg/day).
IV rtPA (0.9mg/kg) was started 120 minutes after stroke
onset. After 24 hours, there was a significant neurological
improvement (NIHSS score of 3). The patient persisted with
total lower left facial palsy and mild left leg paresis, and
the head CT scan showed the same right lenticular nucleus
hypodensity (Figure 1(b)) compatible with an acute cerebral
infarction.
Carotid Doppler ultrasound revealed mild bilateral
atherosclerotic disease with less than 10% stenoses and
transesophageal echocardiography showed left ventricular
ejection fraction of 31% and an atherosclerotic debris of
the aortic arch. Anticoagulation with low-molecular-weight
heparin was initiated 24 hours after IV rtPA.
On the fourth day after treatment, a sudden neurolog-
ical worsening was noted. The patient was alert but did
not respond to simple commands. A conjugate deviation
of the eyes that could not be overcome by voluntary or
reflexive activity was seen, and visual threat showed a right
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homonymous hemianopia. Complete inferior bilateral face
palsy was evidenced by Foix maneuver. Complete right arm
and leg paralysis was noted and the patient was aphasic.
NIHSS score was 22 points. The last dose of low-molecular-
weight heparin was administered 13 hours before symptoms
onset. A new head CT scan showed no significant changes
when compared with the one performed 24 hours after first
IV rtPA treatment (Figure 1(c)).
A thorough and thoughtful discussion regarding the
appropriateness of the second IV thrombolytic treatment
was held with the patient’s family. Intra-arterial thrombolysis
could have been an off-label alternative, but there was no
availability at that moment. A second full-dose (0.9mg/Kg)
IV rtPA therapy was started 4 hours after stroke onset.
Immediate NIHSS score after treatment was 18. Forty-eight
hours later, NIHSS score was 16. The patient persisted with
mild-to-moderate right hemiparesis, moderate aphasia, right
homonymous hemianopia, and dysphagia. Head CT scan
performed 24 and 48 hours (Figure 1(d)) after treatment
showed the previous right lenticular infarction and a new
predominantly subcortical ischemic lesion in the anterior
region of the left middle cerebral artery territory with a PH2
(>30% of the infarcted area with space occupying effect) [11]
hemorrhage. A pneumonia was diagnosed on day 20 and the
patient died 5 days later. Death was attributed to the latter
infectious complication.
We report a case of repeated IV rtPA within less than
5 days in a patient with paroxysmal atrial fibrillation and
recurrent acute ischemic stroke. To the best of our knowledge,
our case represents the third report on repeated systemic
thrombolysis within 5 days between the incident and the
recurrent ischemic stroke [6, 7] and the second one reporting
on repeated IV rtPA treatment in a patient with early
recurrent ischemic stroke associated to atrial fibrillation
[7]. The current case raises several relevant issues related
to repeated use of IV rtPA that warrant discussion: the
potential development of anaphylactic reactions, the risk of
hemorrhagic transformation, and the role of atrial fibrillation
as a marker of early recurrent ischemic stroke and poor
outcome after first and repeated IV thrombolysis.
There are few reports regarding potential anaphylactic
reactions triggered by repeated thrombolysis [9]. Animal
models have demonstrated the formation of antibodies
against rtPA [12, 13]. However, development of these antibod-
ies in humans is unusual [14] and there are only occasional
reports of IV rtPA-related anaphylactic reactions in “real-life”
clinical practice [15]. Moreover, no anaphylactic reactions
have been described among any of the 13 cases of repeated
IV thrombolysis for ischemic stroke reported up to date
(including ours).
Our patient showed a PH2 hemorrhage on follow-up
head CT scans which may have influenced the unfavorable
neurological outcome, though this is controversial. Despite
the short alpha half-life of rtPA (e.g., 4 to 5 minutes), its
repeated use over short periods is contraindicated because of
the risk of major bleeding, mainly intracerebral hemorrhage.
In our patient, the risk of rtPA-associated hemorrhage was
high because of the severity of the second stroke [16], the car-
dioembolic mechanism of the cerebrovascular event (atrial
fibrillation) [17], and her history of congestive heart failure
[18]. Damage to cerebrovascular walls due to free radical
generation during reperfusion injury [19], the production
matrix of metalloproteinases [20], and high concentrations
of cellular fibronectin [21] have been implicated in the
pathophysiology of rtPA-associated hemorrhage. However,
the role of these biomarkers needs to be clarified.
The recovery of our patient was good after the first cere-
brovascular event but she remained severely disabled after the
second one, possibly because of the combination of recanal-
ization failure and the hemorrhagic transformation. A strong
association has been found between atrial fibrillation and
early recurrent ischemic stroke after treatment with IV rtPA
[22].This phenomenonmay be related to the disintegration of
a preexisting intra-atrial thrombus during thrombolysis. As
mentioned before, the risk of cerebral bleeding is also higher
among atrial fibrillation patients after IV rtPA [17]. However,
adverse neurological outcomes in these patients seem to be
related more to recurrent embolization than to hemorrhagic
transformation [22].
In conclusion, evidence-based medicine is the concept
of treating patients according to the best available evidence.
However, for many rare diseases and other situations like the
very early recurrence of cardioembolic stroke in a patient
who has received rtPA, it is often almost impossible to
develop any form of randomized controlled trial. As men-
tioned before, international guidelines recommend avoiding
repeated thrombolysis for patients with recurrent ischemic
stroke within 3 months of the first event. This recommenda-
tion is not founded on randomized clinical trials, but is rather
held on for the sake of patients’ safety. For medical situations
where impending permanent disability is the most probable
scenario, “out-of-the-box” treatments could be used after a
thorough discussion with patients and their families. We are
aware that ourmedical decisionwas not supported by current
guidelines and that most of the complications of systemic
thrombolysis occurwhen recommendations are not followed.
For this reason, based on teaching purposes and hoping
to raise awareness about this important issue, we decided
to report our case with the aim of further contributing to
increase the scarce available evidence suggesting that early
repeated systemic thrombolysis for recurrent ischemic stroke
should be withheld.
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